The diabetes trial is a 54-week study to evaluate an oral medication given along with insulin. Candidates must be between 30 and 65 years of age, and 10 trips to the IU Medical Center are required. For additional information, call 317-274-3948.

The investigational vaccine in the prostate cancer trial is called Provenge, and researchers are studying how it works in advanced prostate cancer patients. The study harvests white blood cells of the immune system, exposes them to a stimulatory molecule that helps them recognize and kill prostate cancer cells and then returns the cells to the body. The vaccine also is designed to delay and diminish the pain caused when prostate cancer cells have spread to bones.

“Prostate cancer vaccines to date are all similar, but Provenge seems to generate a more consistent response,” said Dr. Tom Gardner. “There also has been some indication of improved survival among patients in earlier studies of this investigational procedure.”

Prostate cancer is the top non-skin cancer diagnosed in men in the United States.

Nationally, 29,000 men—700 of them Hoosiers—died from the disease in 2003. For clinical trial information, telephone 317-630-8913 or go to:

www.dendreon.com/technology/den_vaccines.html